Inventiva (IVA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Inventiva, a clinical-stage biopharmaceutical company, has reported a cash position of €13.9 million as of September 2024, with revenues reaching €1.3 million for the first nine months of 2024. The company successfully raised €94.1 million as part of an equity financing initiative, expected to fund operations until mid-2025, and noted a strategic focus on advancing the Phase 3 trial of its lead product candidate, lanifibranor, for MASH/NASH treatment.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
